• Catherine Alix-Panabières, PhD, Director, Laboratory of Rare Human Circulating Cells (LCCRH), Pathology and Onco-Biology Department, University Medical Center of Montpellier, France
  • Robert Anders, MD, PhD, Associate Professor, Pathology, Johns Hopkins
  • Esther Babady, PhD, D (ABMM), FIDSA, Section Head, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center
  • Johan Baeck, MD, Vice President, Clinical Development, Medical Affairs, and Biostatistics and Programming, Jounce Therapeutics
  • Jennifer Dien Bard, PhD, D(ABMM), F(CCM), Director, Clinical Microbiology and Virology, Children’s Hospital Los Angeles; Associate Professor of Pathology (Clinical Scholar), Keck School of Medicine, University of Southern California
  • Dan Barouch, MD, PhD, William Bosworth Castle Professor of Medicine, Harvard Medical School, Ragon Institute of MGH, MIT, and Harvard; Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
  • Lourdes Barrera, PhD, Senior Director, Precision Medicine, Oncology Business Unit, Novartis
  • J. Carl Barrett, PhD, Vice President, Translational Sciences, Oncology iMed, AstraZeneca
  • Kristin G. Beaumont, PhD, Assistant Professor, Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai
  • Gregory J. Berry, PhD, D(ABMM), Director, Molecular Diagnostics, Northwell Health System
  • Matthew J. Binnicker, PhD, D(ABMM), Director of Clinical Virology, Professor of Laboratory Medicine and Pathology, Mayo Clinic
  • Kristin Blouch, Director, Disease Characterization & Strategy, Experimental Medicine Unit, GlaxoSmithKline
  • Genevieve Boland, MD, PhD, Section Head, Melanoma/Sarcoma Surgery; Surgical Director, Termeer Center for Targeted Therapies; Director, Surgical Oncology Research Laboratories, Massachusetts General Hospital
  • Darrell Borger, PhD, Associate Director, Translational Oncology; Head, Integrated Translational Technologies, Oncology Drug Development Unit, Takeda Pharmaceuticals
  • Andrew Brooks, PhD, COO & Director, Technology Development, RUCDR Infinite Biologics; Professor, Genetics, Rutgers University
  • Katherine Call, PhD, Senior Director, Head, Proteogenomics, Sanofi Translational Sciences
  • Daniel Chiu, PhD, A. Bruce Montgomery Professor of Chemistry, University of Washington           
  • Tomas Cihlar, PhD, Vice President, Virology, Gilead
  • Carolyn Compton, MD, PhD, FCAP, Professor, Life Sciences, Arizona State University; Professor of Laboratory Medicine and Pathology, Mayo College of Medicine; CMO, National Biomarker Development Alliance
  • Dana Connors, MSc, PMP, Senior Scientific Project Manager, Cancer, Foundation for the NIH
  • James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center; Professor, Pediatrics and Pathology, Microbiology and Immunology, Ann Scott Carell Chair, Vanderbilt University
  • Biswajit Das, PhD, Principal Scientist, Molecular Characterization, Frederick National Laboratory for Cancer Research
  • M. Khair El Zarrad, PhD, MPH, Deputy Director, Office of Medical Policy, Center for Drug Evaluation & Research, FDA CDER
  • Kenneth Emancipator, MD, Executive Medical Director, Early Oncology Development, Merck & Co., Inc., Kenilworth, NJ, USA
  • Mark T. Esser, PhD, Vice President, Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca
  • D. Clark Files, MD, Associate Professor, Pulmonary and Critical Care Medicine, Wake Forest School of Medicine
  • Shirin Khambata Ford, PhD, Head of Precision Medicine, Clinical Biomarkers and Companion Diagnostics, Daiichi Sankyo
  • Alex Greninger, MD, PhD, Assistant Professor, Laboratory Medicine, University of Washington
  • Sanjay Gurunathan MD, Vice-President, Head of Clinical Sciences, Sanofi Vaccine R&D
  • Samir Hanash MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, University of Texas MD Anderson Cancer Center
  • Fred R. Hirsch, MD, PhD, Executive Director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of Medicine and Pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine; Associate Director, Tisch Cancer Institute
  • Darren Hodgson, PhD, Global Project Leader & Head of Strategy for Translational Medicine, AstraZeneca
  • Dave S.B. Hoon, PhD, Professor and Director, Translational Molecular Medicine, John Wayne Cancer Institute
  • Peter Hotez, MD, PhD, FASTMH, FAAP, Dean, National School of Tropical Medicine; Professor, Departments of Pediatrics, Molecular Virology & Microbiology; Co-Head, Section of Pediatric Tropical Medicine; Health Policy Scholar, Baylor College of Medicine
  • Emma Huang, Director of Data Sciences External Innovation at the California Innovation Center, Johnson & Johnson
  • Thomas Hudson, MD, Senior Vice-President, R&D, CSO, AbbVie
  • Dan Jacobson, PhD, Chief Scientist, Computational Systems Biology, Biosciences, Oak Ridge National Laboratory
  • Filip Janku, MD, PhD, Associate Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center
  • François Jean, PhD, Professor of Virology; Science Advisor, Canadian COVID-19 Therapeutic Task Force; Founder, UBC Facility for Infectious Disease and Epidemic Research, University of British Columbia
  • Krishna Kandarpa, MD, PhD, Director of Research Sciences and Strategic Directions, National Institute of Biomedical Imaging and Bioengineering (NIBIB)
  • Faisal Khan, PhD, Executive Director, Advanced Analytics & AI, AstraZeneca Pharmaceuticals, Inc.
  • Gerald Kost, MD, PhD, MS, FAACC, Fulbright Scholar 2020-2021, ASEAN Member States; Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR); Emeritus Professor, School of Medicine, University of California, Davis
  • Razelle Kurzrock, MD, Senior Deputy Center Director, Clinical Science; Director, CPCT/CTO; Chief, Hematology/Oncology, University of California, San Diego, Moores Cancer Center
  • Hakho Lee, PhD, Associate Professor, Radiology, Harvard Medical School; Director, Biomedical Engineering Program, Center for Systems Biology, Massachusetts General Hospital
  • Mark J. Lee, PhD, D(ABMM), M(ASCP), Assistant Professor, Duke University; Assistant Director, DUHS Clinical Microbiology Labs, Duke University Health System
  • Matthew Lungren, Assistant Professor of Radiology & Associate Director, Center for AI in Medicine & Imaging, Stanford University
  • Holden T. Maecker, PhD, Professor (Research), Microbiology & Immunology; Director, Human Immune Monitoring Center, Stanford University School of Medicine
  • Kathleen M. Mahoney, MD, PhD, Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana-Farber Cancer Institute
  • G. Mike Makrigiorgos, PhD, Professor and Director, Medical Physics & Biophysics Division, Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School
  • Julia Markensohn, PhD, Associate Principal Scientist, Merck
  • Christopher Mason, PhD, Associate Professor, Physiology and Biophysics; Co-director, WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine
  • Marielena Mata, PhD, Director and Diagnostic Lead, Oncology Programs, Pfizer
  • Ian McCaffery, PhD, Vice President, Head of Precision Medicine and Companion Diagnostics, AbbVie
  • Michael J. Mina, MD, PhD, Assistant Professor of Epidemiology, Harvard T.H. Chan School of Public Health
  • Jennifer Morrissette, PhD, Director, Clinical CytoGenomics Laboratory, Associate Professor, Pathology, University of Pennsylvania
  • Monica Motwani, PhD, Director (Research Fellow), Translational Oncology, Abbvie
  • James H. Nichols, PhD, DABCC, FAACC, Professor, Pathology, Microbiology and Immunology; Medical Director, Clinical Chemistry and POCT, Vanderbilt University Medical Center
  • John Nolan, PhD, Professor, The Scintillon Institute
  • Dave O’Connor, PhD, UW Medical Foundation Professor, Pathology & Laboratory Medicine, University of Wisconsin-Madison
  • Mene Pangalos, PhD, Executive VP, Biopharmaceuticals R&D, AstraZeneca
  • Malileh Poorfarhani, Director, Digital Health and R&D, Bayer
  • Mark Poznansky, MD, PhD, Associate Professor, Medicine, Vaccine and Immunotherapy Center, Massachusetts General Hospital
  • Shashi Ramaiah, PhD, Head, Safety Biomarkers, Translational Sciences, Pfizer
  • Nadeem Riaz, MD, Associate Director, Immunogenomics and Precision Oncology Platform, Radiation Oncology, Memorial Sloan Kettering Cancer Center
  • John Rossi, PhD, Senior Director, Translational Medicine, Kite, A Gilead Company
  • Neville Sanjana, PhD, Core Faculty Member, New York Genome Center; Assistant Professor, Biology, Neuroscience and Physiology, New York University
  • Robert Schlaberg, MD, PhD, Assistant Professor, Pathology, University of Utah; Medical Director, ARUP Laboratories; Co-Founder & CMO, IDbyDNA
  • Emmett Schmidt, PhD, Distinguished Scientist & Executive Director, Merck Research Labs
  • Hanneke Schuitemaker, PhD, Vice President, Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.; Professor, Virology, Amsterdam University Medical Center
  • Ajay Shah, PhD, MBA, Executive Director & Head of IT for Translational Medicine, Bristol-Myers Squibb
  • Alexander Sherman, Director, Center for Innovation and Bioinformatics, Massachusetts General Hospital
  • Patricia R. Slev, PhD, Section Chief, Immunology; Medical Director, Immunology Core Laboratory; Associate Professor, University of Utah School of Medicine
  • Jeremy C. Smith, PhD, Governor's Chair and Director, University of Tennessee/Oak Ridge National Laboratory Center for Molecular Biophysics
  • Michael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University
  • Elizabeth Somers, PhD, Diagnostic Pathway Lead, Global AD Franchise, Eisai
  • Timothy Stenzel, MD, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA
  • Zhen Su, MD, MBA, Senior Vice President and Global Head, Oncology Franchise, Merck KGaA
  • Benjamin tenOever, PhD, Professor of Microbiology, Irene and Dr. Arthur M. Fishberg Professor of Medicine; Director, Virus Engineering Center for Therapeutics and Research (VECToR); Co-Director, Microbiology Main Training Area, Icahn School of Medicine at Mount Sinai
  • Apostolia-Maria Tsimberidou, MD, PhD, Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center
  • Aparna Vasanthakumar, PhD, Principal Research Scientist, Pharmacogenetics and Pharmacogenomics, Genomics Research Center, AbbVie
  • Victor E. Velculescu, MD, PhD, Professor, Oncology, Pathology and Medicine; Co-Director, Cancer Genetics and Epigenetics; Associate Cancer Center Director, Precision Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
  • Andrea Webber, PhD, Assistant Head, Clinical Biomarkers, Translational Oncology, Merck
  • James A. Wells, PhD, Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences, University of California, San Francisco
  • Theresa Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, Hillman Cancer Center, University of Pittsburgh School of Medicine
  • Alan H.B. Wu, PhD, Professor, Laboratory Medicine, University of California, San Francisco; Chief, Chemistry and Toxicology, San Francisco General Hospital
  • Joshua Xu, PhD, Branch Chief, Research-to-Review (R2R), Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, FDA

 

 


Premier Sponsors

NeoGenomics

Seegene